[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 230,787
  • Shares Outstanding, K 116,559
  • Annual Sales, $ 6,650 K
  • Annual Income, $ -136,320 K
  • EBIT $ -139 M
  • EBITDA $ -130 M
  • 60-Month Beta 2.53
  • Price/Sales 38.76
  • Price/Cash Flow N/A
  • Price/Book 1.44

Options Overview Details

View History
  • Implied Volatility 156.07% (+22.87%)
  • Historical Volatility 151.27%
  • IV Percentile 20%
  • IV Rank 5.12%
  • IV High 1,257.44% on 11/18/25
  • IV Low 96.61% on 06/11/25
  • Expected Move (DTE 12) 0.3485 (17.60%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 519
  • Volume Avg (30-Day) 890
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 7,381
  • Open Int (30-Day) 7,874
  • Expected Range 1.6315 to 2.3285

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.28
  • Number of Estimates 5
  • High Estimate $-0.27
  • Low Estimate $-0.29
  • Prior Year $-0.29
  • Growth Rate Est. (year over year) +3.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5900 +24.53%
on 05/19/26
2.8800 -31.25%
on 05/29/26
-0.3800 (-16.10%)
since 05/05/26
3-Month
1.0400 +90.38%
on 03/19/26
2.8800 -31.25%
on 05/29/26
+0.6000 (+43.48%)
since 03/05/26
52-Week
0.9100 +117.58%
on 08/11/25
2.8800 -31.25%
on 05/29/26
+0.6400 (+47.76%)
since 06/05/25

Most Recent Stories

More News
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued...

FATE : 1.9800 (-10.41%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent...

FATE : 1.9800 (-10.41%)
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal cancer Detection of FT836 in the peripheral blood and tumor tissue illustrates...

FATE : 1.9800 (-10.41%)
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem...

FATE : 1.9800 (-10.41%)
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

AVAI : 0.1800 (-5.26%)
BIOA : 15.70 (-7.76%)
LCTX : 1.1900 (-1.65%)
GERN : 1.1700 (-3.31%)
FATE : 1.9800 (-10.41%)
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END

CHRS : 1.4500 (-7.94%)
GTBP : 0.4364 (-8.51%)
FATE : 1.9800 (-10.41%)
ARTV : 6.85 (-10.81%)
IBRX : 6.92 (-5.08%)
Fate Therapeutics: Q1 Earnings Snapshot

Fate Therapeutics: Q1 Earnings Snapshot

FATE : 1.9800 (-10.41%)
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate...

FATE : 1.9800 (-10.41%)
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B...

FATE : 1.9800 (-10.41%)
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines...

FATE : 1.9800 (-10.41%)

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 2.3917
2nd Resistance Point 2.2933
1st Resistance Point 2.1367
Last Price 1.9800
1st Support Level 1.8817
2nd Support Level 1.7833
3rd Support Level 1.6267

See More

52-Week High 2.8800
Fibonacci 61.8% 2.1275
Last Price 1.9800
Fibonacci 50% 1.8950
Fibonacci 38.2% 1.6625
52-Week Low 0.9100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.